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Introduction to special issue on Advances in blood-based
biomarkers of Alzheimer’s diseaseBlood-based biomarkers related to Alzheimer’s disease
(AD) have significant potential to advance both the diag-
nostic and therapeutic processes and procedures related to
this devastating disease. In light of this potential, a signifi-
cant amount of work has been conducted in recent years.
In fact a PubMed search (6/2016) using the terms “blood
based biomarkers AND Alzheimer’s disease” yielded 474
hits with an overwhelming 48% of these articles being pub-
lished from 2013–2016. This special issue of Alzheimer’s &
Dementia: Diagnosis, Assessment & Disease Monitoring on
Advances in blood-based biomarkers of Alzheimer’s disease
is intended to provide a broad-based snapshot regarding
several aspects of the space. This special issue contains ad-
vancements in the space spanning newer technologies (e.g.,
exosome biomarkers) as well as progression in markers that
have been more extensively studied (e.g., autoantibodies,
apoJ). The special issue is broken down by categories that
broadly correspond to a specific putative context of use
(COU).
Blood-based biomarkers offer an excellent complemen-
tary information to well-established cerebrospinal fluid
(CSF), imaging (MRI, PET, other) biomarkers for the estab-
lishment of multistage processes for diagnostic and thera-
peutic strategies, such as what has been of tremendous
utility in other areas of medicine (e.g., cancer [1]). The inten-
tion of these blood-based biomarkers is to increase access to
CSF, imaging, and other biomarker modalities as well as to
provide novel information to enhance the scientific under-
standing of the complete biological dysfunction associated
with AD and other neurological diseases.
This special issue has been conceptually divided into
broadly defined categories beginning with methodological
considerations, to a set of possible context of uses (COUs)
and ends with a study highlighting ethnic considerations in
this space of scientific investigation.1. Methodological considerations
This issue begins with two manuscripts intended to pro-
vide an update and overview of novel methods as well as
highlight areas of concern when comparing across platforms
and tissue type. First, an overview of advancements in thehttp://dx.doi.org/10.1016/j.dadm.2016.06.003
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based biomarkers is provided by Andreasson, Blennow,
and Zetterberg [2]. This review describes single-molecule
array (Sioma), single-molecule counting, proximity exten-
sion assay and MagQu platforms as well as provides exam-
ples of recent relevant publications using these methods in
both the blood and CSF space. Next, O’Bryant et al. [3]
conduct a follow-up study to the 2015 guidelines [4] project
that directly compares biomarker assay results across
different assay technologies as well as serum and plasma.
This work highlights the concerns when making cross-
study comparisons and generalizations when findings are
based on serum versus plasma as well as different assay plat-
forms or technologies. This work is directly relevant to the
movement from biomarker discovery to locked-down
methods for biomarker validation.2. Understanding immune dysfunction in Alzheimer’s
disease
Next, a series of studies highlight the importance of im-
mune dysregulation in AD. First, Guedes et al. examine
blood-derived monocytes (BDMs) and monocyte-derived
macrophages (MDMs) isolated from AD, mild cognitive
impairment (MCI), and control subjects. These authors
found that chemokine/chemokine receptor (CCL2/CCR2)
axis and MDM-mediated phagocytosis of Ab were altered.
They also found alterations in triggering receptor expressed
on myeloid cells 2 (TREM2) and expression of miRNAs.
Together, this work provides additional support for dysfunc-
tion of the immune system in AD pathogenesis and may
point toward a specific endophenotype of inflammatory
dysfunction in AD. Next, Tampubolon [5] analyzed data
from the English Longitudinal Study of Ageing, a nationally
representative study of the older English population to deter-
mine if inflammation (CRP, fibrinogen) was associated with
worsening of episodic memory. Multiple waves of data were
analyzed, and results suggested that elevated inflammation
was associated with poorer episodic memory, particularly
among the oldest old (i.e., 75 years). Together, these
studies continue to point toward the importance of immune
dysregulation in AD and cognitive aging; however, they doation. This is an open access article under the CC BY-NC-ND license (http://
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viduals only or this effect is associated with a third variable
of general worsening of health that is also related to cogni-
tive aging. Despite this, this work supports the need for addi-
tional work in this area. It remains to be determined whether
this line of work supports a potential COU of identification
of specific patients most likely to benefit from targeted
anti-inflammatory interventions.3. Predicting conversion from MCI to AD or risk for
incident AD or dementia
An important potential COU for AD biomarker science is
the identification of risk for progression (e.g., progression
fromMCI to AD, risk for incident AD/dementia from normal
cognition). Such biomarkers can potentially be useful for clin-
ical trial design targeting specific populations with increased
risk for imminent cognitive decline. Enrichment of these spe-
cific subjects into trials has the benefit of reducing the diluting
effect of enrolling those subjects not likely to progress. This
topic area begins with work by Winston and colleagues [6]
examining the utility of neuronally derived exosomes
(NDEs) in predicting conversion from MCI to dementia. Al-
terations in plasma NDE levels of p-tau, Ab1-42, NRGN,
and REST were found among AD and MCI cases that con-
verted to ADwhen compared to stable MCI cases and normal
controls. Additionally, when injected into the right hippocam-
pus of wild-type (C57/BL6) mice, NDEs fromMCI cases that
converted to AD increased p-tau when compared to NDEs
from normal controls and stable MCI cases. Next, Weinstein
et al. [7] examine plasma clusterin from 1532 nondemented
subjects of the Framingham Study Offspring cohort to deter-
mine how this putative biomarker predicts incident dementia
and stroke. Among older adults, plasma clusterin was associ-
ated with significantly increased risk for dementia; however,
plasma clusterin was related to a reduced risk of dementia
and stroke among younger participants suggesting an age-
effect when interpreting the predictive utility of this putative
biomarker. These studies clearly support the potential use of
blood-based biomarkers when considering the COU of pre-
dicting future risk. A next step would be to explicitly test
this specific COU with these markers either in baseline
samples from independent prospective studies (with direct
application of specific cut-scores) or within new prospectively
designed studies.4. Identifying endophentoypes within AD
Recent work has begun to study the link between
biomarker levels and specific clinically relevant outcomes
(e.g., memory scores, structural MRI outcomes) [8]. In this
issue, Bettcher et al. [9] study MCP-1 and eotaxin-1 levels
among controls, MCI, and AD cases in relation to memory
abilities as well as medial temporal lobe volumes. When
both chemokines were elevated, memory scores were specif-
ically poorer. Additionally, exploratory analyses suggestedthat these chemokine elevations were also associated with
smaller left-medial temporal lobe volumes. Whether this
work has potential to lead to a COU of identification of
memory impairment remains unanswered; however, this
work is illustrative of how specific clinically relevant out-
comes (i.e., memory capacity, structural MRI biomarkers)
can be used as outcome variables in blood-based biomarker
work in addition to dichotomous outcomes of disease
presence.5. Blood biomarkers related to AD presence
The most studied COU for blood-based biomarkers in the
AD space has been related to AD presence. In this issue, a
series of publications are included that examine a broad
range of biomarkers in relation to AD presence. First, Gupta
et al. [10] examine baseline and 18-month follow-up plasma
apoJ (aka clusterin) concentrations in the AIBL cohort. The
authors found that apoJ levels were significantly higher
among MCI and AD cases at both time points and were
also correlated with standardized uptake value ratio PETam-
yloid levels and hippocampal volume. Next, DeMarshall
et al. [11] find excellent accuracy in separating MCI from
normal controls as well as AD using autoantibodies. Savica
et al. [12] analyze plasma sphingolipid changes among
autopsy-confirmed AD, Lewy Body Dementia (DLB), and
control subjects. The authors found significant plasma cer-
amide alterations and monohexosylceramide alterations
between dementia cases (AD and DLB) and controls sug-
gesting that these biomarkers may have utility in identifying
possible AD and/or DLB pathology. Next, Li et al. [13]
analyze data from the Atherosclerosis Risk In Communities
study in an attempt to cross-validate the cross-sectional
detection of AD with plasma phospholipids found in a
recently highly publicized article [14]. Among the 10 previ-
ously identified phospholipids altered in dementia, only
alteration in PC aa C36:6 was associated with dementia
prevalence in this independent cohort. The combined model
of all phospholipids was not able to accurately classify
dementia cases in this cross-sectional analysis. Finally,
O’Bryant et al. [15] created the locked-down referent cohort
for an AD blood screen intended for primary care use and
demonstrated excellent positive and negative predictive
values when compared to existing screening tests.6. Considering ethnicity in AD blood biomarkers
Finally, Royall and Palmer [16] continue their efforts in
understanding blood biomarkers related to their previously
identified latent dementia phenotype “d”. Work from this
collaborative group has previously demonstrated alterations
in serum levels of thrombopoetin (THPO), which these au-
thors found was significantly an ethnically equivalent homo-
log of d but only for non-Hispanic whites. Although THPO
has not been consistently related to AD status across studies
or assay platforms, this work clearly demonstrates the
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biomarkers, as has been shown the case for many biomarkers
in other diseases (e.g., ethnic adjustments for eGFR levels).
To move from discovery to clinic, the study of ethnic impact
on biomarkers is a necessary and important step, which this
work further supports.
When taken as a whole, this special issue reflects several
significant advancements for the field of AD blood-based bio-
markers. First, this work highlights novel techniques and
methodological considerations of importance for progress of
the field. When combined with the 2015 guidelines for pre-
analytic processing, this work can greatly facilitate the identi-
fication of novel biomarkers as well as assist in moving from
biomarker discovery to locked-down validation. Additionally
contained within this special issue are advancements of newer
technologies (ultrasensitive technologies, exosomes) as well
as continued movement on previously studied methods and
markers (autoantibodies, blood-based algorithm for AD
screening). This special issue is intended to aid the reader in
gaining an understanding of recent advancements in the space
of AD blood-based biomarkers. The special issue reflects a
substantial effort by DADM editor, Peter Snyder, as well as
members of the Blood-Based Biomarker Professional Interest
Area of the International Society to Advance Alzheimer’s
Research and Treatment and would not have been possible
without their support.
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